FDA Vaccines Chief Exit: Social media erupted following reports that the head of the FDA's vaccines unit will leave at the end of April, sparking immediate after-hours gains for Moderna shares. Traders interpret the departure as a potential easing of regulatory pressures on mRNA therapies. Discussions emphasize volatility opportunities amid shifting agency dynamics.
Patent Litigation Resolved: Moderna's $950 million settlement in a Covid vaccine patent dispute earlier this week exceeded expectations by being lower than anticipated. Shares surged over 8% premarket, with users hailing it as a major de-risking catalyst. The deal underscores resilience in the company's legal and financial positioning.
Strong Yearly Performance: With shares up 68% year-to-date, conversations spotlight pipeline advancements like flu vaccines despite prior FDA hurdles. Optimism swirls around reduced litigation overhang and potential approvals. Overall sentiment remains bullish on Moderna's trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Moderna Insider Trading Activity
Moderna insiders have traded $MRNA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:
- STEPHEN HOGE (President) sold 160,009 shares for an estimated $7,814,839
- SHANNON THYME KLINGER (Chief Legal Officer) sold 13,885 shares for an estimated $726,046
- NOUBAR AFEYAN sold 23,853 shares for an estimated $703,305
- ABBAS HUSSAIN sold 504 shares for an estimated $13,910
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Moderna Hedge Fund Activity
We have seen 258 institutional investors add shares of Moderna stock to their portfolio, and 396 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 15,741,014 shares (+127.9%) to their portfolio in Q4 2025, for an estimated $464,202,502
- CAPITAL WORLD INVESTORS added 12,828,040 shares (+inf%) to their portfolio in Q4 2025, for an estimated $378,298,899
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 6,254,709 shares (-79.7%) from their portfolio in Q4 2025, for an estimated $184,451,368
- ALYESKA INVESTMENT GROUP, L.P. added 3,228,531 shares (+inf%) to their portfolio in Q4 2025, for an estimated $95,209,379
- BNP PARIBAS FINANCIAL MARKETS added 3,058,933 shares (+279.7%) to their portfolio in Q4 2025, for an estimated $90,207,934
- BLACKROCK, INC. added 2,977,816 shares (+10.1%) to their portfolio in Q4 2025, for an estimated $87,815,793
- CITADEL ADVISORS LLC removed 1,408,601 shares (-70.9%) from their portfolio in Q4 2025, for an estimated $41,539,643
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Moderna Analyst Ratings
Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 3 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/23/2026
- Leerink Partners issued a "Underperform" rating on 11/21/2025
- B of A Securities issued a "Underperform" rating on 11/10/2025
- JP Morgan issued a "Underweight" rating on 10/23/2025
- UBS issued a "Buy" rating on 10/23/2025
To track analyst ratings and price targets for Moderna, check out Quiver Quantitative's $MRNA forecast page.
Moderna Price Targets
Multiple analysts have issued price targets for $MRNA recently. We have seen 12 analysts offer price targets for $MRNA in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Edward Tenthoff from Piper Sandler set a target price of $69.0 on 02/23/2026
- Cory Kasimov from Evercore ISI Group set a target price of $35.0 on 02/17/2026
- Salveen Richter from Goldman Sachs set a target price of $41.0 on 02/17/2026
- Luca Issi from RBC Capital set a target price of $30.0 on 02/17/2026
- Eliana Merle from UBS set a target price of $34.0 on 01/07/2026
- Andrew Tsai from Jefferies set a target price of $30.0 on 12/12/2025
- Matthew Harrison from Morgan Stanley set a target price of $28.0 on 12/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
